Aclarubicin

Summary

Aclarubicin (CHEMBL502620) is a phase-3 clinical-stage small-molecule antimicrobial agent (ATC L01DB04); indicated across 4 conditions including neoplasm and acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01DB04
• Indications: 4 conditions
• Clinical trials: 11
• Chemistry: 811.9 Da · C42H53NO15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL502620
Name	Aclarubicin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	451415
ChEBI	CHEBI:74619
ATC	L01DB04
Molecular formula	C42H53NO15
Molecular weight	811.9
InChIKey	USZYSDMBJDPRIF-SVEJIMAYSA-N

SMILES: CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O

IUPAC name: methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate

ChEBI definition: An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.

Pharmacological roles (ChEBI): antimicrobial agent, EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor, apoptosis inducer, antineoplastic agent.

Other ChEBI roles (chemical / environmental): bacterial metabolite.

Also known as: Aclacinomycin a, Aclarubicin, Aclarubicin hydrochloride, Aclarubicina, Aclarubicine, NSC-208734, Aclacinomycin, Aclacinomycin A, ACLARUBICIN, ACLACINOMYCIN A, ACLARUBICINE, aclarubicin

Parent form; salt/anhydrous children: CHEMBL1697719

Patent coverage: 7,527 distinct patent families (30,150 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 30,043 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Prostaglandin G/H synthase 1, 72 kDa type IV collagenase.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2B	6.15	Ki	704	nM	CHEMBL_ACT_7625086
HTR2B	5.96	IC50	1106	nM	CHEMBL_ACT_7625085
MMP2	5	IC50	9900	nM	CHEMBL_ACT_369001

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
leukemia	2	MONDO:0005059	EFO:0000565
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1/PHASE2	3
PHASE4	1
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03026842	PHASE4	UNKNOWN	Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)
NCT05726110	PHASE3	RECRUITING	Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
NCT07486726	PHASE1/PHASE2	NOT_YET_RECRUITING	Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
NCT07535710	PHASE1/PHASE2	NOT_YET_RECRUITING	Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
NCT07535762	PHASE2	NOT_YET_RECRUITING	Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
NCT01690507	PHASE1/PHASE2	COMPLETED	Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
NCT03045627	PHASE2	UNKNOWN	Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients
NCT03181815	PHASE2	UNKNOWN	Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
NCT04254640	PHASE2	UNKNOWN	Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
NCT02723448	PHASE1	COMPLETED	Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy
NCT05805072	Not specified	UNKNOWN	Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).